Randomised prospective studies assessing differences in clinical outcome in patients with advanced melanoma according to high/low cytokines levels (i.e., biomarker-stratified study design) are needed to confirm the role of IL-6, HGF, and MCP-2 as potential predictive biomarkers of ICI efficacy for clinical use. The gene discussed is IL6; the disease is melanoma.